Table I.
Baseline Characteristics
| Parameter | Treatment Group | Total (n=304) | P Valuea | |
|---|---|---|---|---|
| T/V (n=152) | B/A (n=152) | |||
| Male, No. (%) | 94 (61.84) | 102 (67.11) | 196 (64.47) | .402 |
| Race, No. (%) | ||||
| White | 113 (74.34) | 111 (73.03) | 224 (73.68) | .894 |
| Black | 31 (20.39) | 34 (22.37) | 65 (21.38) | |
| Asian | 7 (4.61) | 6 (3.95) | 13 (4.28) | |
| American Indian/Alaska Native/Other | 1 (0.66) | 1 (0.66) | 2 (0.66) | |
| Hispanic, No. (%) | 62 (40.79) | 68 (44.74) | 130 (42.76) | .562 |
| Age, yb | 61.2 (9.9) | 60.4 (11.0) | 60.8 (10.4) | .507 |
| SBP, mm Hgb | 141.4 (21.6) | 142.7 (19.2) | 142.0 (20.4) | .577 |
| DBP, mm Hgb | 77.2 (11.6) | 76.4 (12.4) | 76.8 (12.0) | .549 |
| Heart rate, beats/minb | 74.0 (11.7) | 75.6 (11.3) | 74.8 (11.5) | .232 |
| Weight, kgb,c | 94.6 (22.9) | 92.7 (19.4) | 93.7 (21.2) | .417 |
| Height, cmb | 168.5 (10.4) | 169.0 (10.5) | 168.8 (10.4) | .693 |
| UACR, g/gb,d | 0.94 (1.39) | 0.72 (0.92) | 0.83 (1.18) | .10 |
| UACR <0.2 g/g, No. (%)d | 47 (30.9) | 51 (33.6) | 98 (32.2) | .71 |
| eGFR, mL/min/1.73 m2 b,e | 58.6 (26.8) | 61.4 (28.6) | 60.0 (27.7) | .378 |
| HbA1c, %b,f | 8.0 (1.7) | 8.2 (1.7) | 8.1 (1.7) | .382 |
| Potassium, mmol/Lb | 4.6 (0.6) | 4.6 (0.5) | 4.6 (0.6) | .872 |
Abbreviations: B/A, benazepril/amlodpine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; T/V, trandolapril/verapamil SR; UACR, urinary albumin/creatinine ratio. aFrom Fisher’s exact test for categorical measures, one‐way ANOVA for continuous measures, and Wilcoxon test for median comparisons. bMean (SD). cT/V, n=152; B/A, n=151; total, N=303. dT/V, n=149; B/A, n=152; total, N=299. eT/V, n=146; B/A, n=147; total, N=293.fT/V, n=151; B/A, n=152; total, N=303.